


IFN
CASE QA0278 NP

CERTIFICATE OF MAILING

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Joseph C. Wang
Type or print name


Signature


Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Art Unit: 1614

CHEN ET AL.

APPLICATION NO: 10/773,002

FILED: FEBRUARY 5, 2004

FOR: PROCESS FOR PREPARING PYRROLOTRIAZINE KINASE
INHIBITORS

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

This Information Disclosure Statement is being filed in accordance with 37 C.F.R. §1.97(b).

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

Some of the listed references were cited in a search report in a corresponding PCT International application. Copies of these references and the search report are enclosed herewith.

Also, copies of the other cited references are enclosed herewith.

Applicants bring to the Examiner's attention the following U.S. patent applications and/or patents having co-pendency with the instant application and assigned to the present assignee:

US Pat. 6,670,357, granted 12/30/03 (Serial No. 10/036,293, filed 11/7/01)
US Publ. No. 2002/0065270A1, published 5/30/02 (Serial No. 09/747,195, filed 12/22/00)
US Publ. No. 2002/0137747A1 (Serial No. 09/891,750, filed 6/26/01)
US Publ. No. 2003/0139435A1 (Serial No. 10/183,179, filed 6/26/02)
US Publ. No. 2003/0186982A1, published 10/2/03 (Serial No. 10/289,010, filed 11/6/02)
US Publ. No. 2003/0186983A1, published 10/2/03 (Serial No. 10/294,281, filed 11/14/02)
US Publ. No. 2003/0232831A1, published 12/18/03 (Serial No. 10/420,445, filed 4/22/03)
US Publ. No. 2004/0023992A1, published 2/5/04 (Serial No. 10/440,864, filed 5/19/03)
US Publ. No. 2004/0063707A1, published 4/1/04 (Serial No. 10/622,593, filed 7/18/03)
US Publ. No. 2004/0063708A1, published 4/1/04 (Serial No. 10/633,997, filed 8/4/03)
US Publ. No. 2004/0072832A1, published 4/15/04 (Serial No. 10/623,171, filed 7/18/03)
US Publ. No. 2004/0077858A1, published 4/22/04 (Serial No. 10/622,280, filed 7/18/03)
US Publ. No. 2004/0082582A1, published 4/29/04 (Serial No. 10/420,399, filed 3/22/03)
US Publ. No. 2004/0142931A1, published 7/22/04 (Serial No. 10/736,476, filed 12/15/03)
US Publ. No. 2004/0229877A1, published 11/18/04 (Serial No. 10/696,178, filed 10/29/03)
US application Serial No. 09/573,829, filed 5/18/00
US application Serial No. 10/678,388, filed 10/3/03
US application Serial No. 10/970,420, filed 10/21/04
US application Serial No. 11/008,719, filed 12/9/04
US application Serial No. 11/019,899, filed 12/22/04
US application Serial No. 11/019,901, filed 12/22/04
US application Serial No. 60/580,194, filed 6/16/04
US application Serial No. 60/584,289, filed 6/30/04
US application Serial No. 60/584,382, filed 6/30/04
US application Serial No. 60/584,768, filed 7/1/04
US application Serial No. 60/600,935, filed 8/12/04
US application Serial No. 60/620,784, filed 10/21/04
US application Serial No. 60/639,178, filed 12/23/04

In each of the above patents and/or applications, there are described compounds having a pyrrolotriazine core, and/or compounds having p38 inhibitory activity, and/or processes or intermediates for making such compounds.

A copy of the specification, drawings and claims as currently pending is attached for each above-identified co-pending application.

PLEASE DO NOT PRINT any of the above information that is not published on any patent resulting from the subject application.

Consideration of each above listed application is earnestly solicited, since unpublished patent applications are contemplated as IDS material; please see 37 CFR §98(a)(2)(iii) and note the last two sentences of MPEP §609(III)(D).

Further, in keeping with MPEP §609, subsec. (III)(C)(2), 2nd para, line 10 to end of the paragraph (especially note lines 18-25), PLEASE RETURN A COPY OF THIS LETTER with the Examiner's initials adjacent to each above listing so that applicant will know that each listed application has been considered, as required by PTO policy.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,



Joseph C. Wang
Attorney for Applicants
Reg. No. 44,391

Bristol-Myers Squibb Company
Patent Department
P.O. Box 4000
Princeton, NJ 08543-4000
609-252-4931

Date: January 31, 2005

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)



Sheet 2 of 2

ATTY. DOCKET NO.
QA0278 NP
APPLICATION NO.
10/773,002
APPLICANT
CHEN ET AL.
FILING DATE
FEBRUARY 5, 2004

Group
1614

U.S. PATENT APPLICATION PUBLICATIONS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	2AA	2002/0065270	5/30/02	Moriarty et al.			
	2AB	2002/0137747	9/26/02	Moriarty et al.			
	2AC	2003/0139435	7/24/03	Ahmed et al.			
	2AD	2003/0186982	10/2/03	Godfrey, Jr. et al.			
	2AE	2003/0186983	10/2/03	Mastalerz et al.			
	2AF	2003/0232831	12/18/03	Dyckman et al.			
	2AG	2004/0023992	2/5/04	Das et al.			
	2AH	2004/0063707	4/1/04	Bhide et al.			
	2AI	2004/0063708	4/1/04	Bhide et al.			
	2AJ	2004/0072832	4/15/04	Bhide et al.			
	2AK	2004/0077858	4/22/04	Bhide et al.			
	2AL	2004/0082582	4/29/04	Dyckman et al.			
	2AM	2004/0142931	7/22/04	Vite et al.			
	2AN	2004/0229877	11/18/04	Leftheris et al.			
	AO						
	AP						
	AQ						
	AR						
	AS						
	AT						
	AU						
	AV						
	AW						
	AX						
	AY						
	AZ						

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)



ATTY. DOCKET NO.
QA0278 NP
APPLICATION NO.
10/773,002
APPLICANT
CHEN ET AL.
FILING DATE
FEBRUARY 5, 2004

Group
1614**U.S. RELATED PATENT APPLICATIONS**

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
AA						
AB						
AC						
AD						
AE						
AF						
AG						
AH						
AI						
AJ						
AK						
AL						
AM						

U.S. PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
AN	6,670,357	12/30/03	Leftheris et al.			

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION YES	NO
AO	WO 00/71129	11/30/00	PCT			<input type="checkbox"/>	<input type="checkbox"/>
AP	WO 01/14378	3/1/01	PCT			<input type="checkbox"/>	<input type="checkbox"/>
AQ	WO 02/40486	5/23/02	PCT			<input type="checkbox"/>	<input type="checkbox"/>
AR	WO 03/090912	11/6/03	PCT			<input type="checkbox"/>	<input type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

AS	Taft, W.E. et al., "as-Triazines. I. 5-Sulfanilamido Derivatives and Intermediates", J. Med. Chem., Vol. 10, pp. 883-887 (1967)
----	---

EXAMINER**DATE CONSIDERED**

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.